Precision peptide disruptors: The next generation of targeted therapeutics in oncology

被引：0

作者：

O'Gorman, Bria ^{[1
]}

Cooke, Sean F. ^{[1
]}

Blair, Connor M. ^{[1
]}

机构：

[1] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Scotland

来源：

CELLULAR SIGNALLING | 2025年 / 132卷

基金：

英国工程与自然科学研究理事会; 英国医学研究理事会;

关键词：

Peptide disruptors; Protein-protein interactions; Precision medicine; Oncology; TRANSCRIPTION FACTOR; CANCER; PCNA; ANTAGONIST; PHOSPHORYLATION; INHIBITION; EXPRESSION; MIMICKING; THERAPY; PATHWAY;

D O I：

10.1016/j.cellsig.2025.111783

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Therapeutically targeting the pathologically remodelled protein-protein interaction network in cancer with peptide disruptors increasingly represents a clinically attractive approach to treating recalcitrant cancers. In this review, we map the pre-clinical and clinical-stage peptide disruptor landscape within an oncology-specific context and discuss key clinical examples that are making significant impact to patients; demonstrating a key role for peptide disruptors in precision medicine as a next-generation targeted therapeutic.

引用

页数：8

共 122 条

[1]

Aileron Therapeutics, 2022, A Study of ALRN-6924 for the Prevention of Chemotherapy-Induced Side Effects (Chemoprotection) (NCT04022876) Internet

[2]

Aileron Therapeutics, 2023, A Study of ALRN-6924 for Protection of ChemotherapyInduced Side Effects in Patients With TP53-Mutant Breast Cancer (NCT05622058) Internet

[3]

[Anonymous], 2023, University of Pennsylvania CART-EGFRvIII + Pembrolizumab in GBM Internet. ClinicalTrials.gov

[4] Helix capping [J].

Aurora, R ;

Rose, GD .

PROTEIN SCIENCE, 1998, 7 (01) :21-38

[5] A sychnological cell penetrating peptide mimic of p21WAF1/CIP1 is pro-apoptogenic [J].

Baker, Rachael D. ;

Howl, John ;

Nicholl, Iain D. .

PEPTIDES, 2007, 28 (04) :731-740

[6] Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue [J].

Beaulieu, Marie-Eve ;

Martinez-Martin, Sandra ;

Kaur, Jastrinjan ;

Cano, Virginia Castillo ;

Masso-Valles, Daniel ;

Felip, Laia Foradada ;

Lopez-Estevez, Sergio ;

del Pozo, Erika Serrano ;

Thabussot, Hugo ;

Soucek, Laura .

CANCERS, 2023, 15 (03)

[7] Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy [J].

Beaulieu, Marie-Eve ;

Jauset, Toni ;

Masso-Valles, Daniel ;

Martinez-Martin, Sandra ;

Rahl, Peter ;

Maltais, Loika ;

Zacarias-Fluck, Mariano F. ;

Casacuberta-Serra, Silvia ;

Serrano del Pozo, Erika ;

Fiore, Christopher ;

Foradada, Laia ;

Castillo Cano, Virginia ;

Sanchez-Hervas, Meritxell ;

Guenther, Matthew ;

Romero Sanz, Eduardo ;

Oteo, Marta ;

Tremblay, Cynthia ;

Martin, Genesis ;

Letourneau, Danny ;

Montagne, Martin ;

Morcillo Alonso, Miguel Angel ;

Whitfield, Jonathan R. ;

Lavigne, Pierre ;

Soucek, Laura .

SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (484)

[8] Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function [J].

Beltran, A. S. ;

Graves, L. M. ;

Blancafort, P. .

ONCOGENE, 2014, 33 (39) :4767-4777

[9] Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation [J].

Beneker, Chad M. ;

Rovoli, Magdalini ;

Kontopidis, George ;

Roering, Michael ;

Galda, Simeon ;

Braun, Sandra ;

Brummer, Tilman ;

McInnes, Campbell .

JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (08) :3886-3897

[10] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer [J].

Blaquier, Juan Bautista ;

Cardona, Andres Felipe ;

Recondo, Gonzalo .

FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 6 7 8 9 10 →